| Company Name: |
T&W GROUP |
| Tel: |
021-61551611 13296011611 |
| Email: |
contact@trustwe.com |
2',3',5'-Tri-O-benzoyl-5-iodouridine manufacturers
|
| | 2',3',5'-Tri-O-benzoyl-5-iodouridine Basic information |
| Product Name: | 2',3',5'-Tri-O-benzoyl-5-iodouridine | | Synonyms: | O2',O3',O5'-tribenzoyl-5-iodo-uridine;2',3',5'-Tri-O-benzoyl-5-iodouridine;2’,3’,5’-Tri-O-benzoyl-5-iodouridine (see GL100179);Uridine, 5-iodo-, 2',3',5'-tribenzoate;2’,3’,5’-Tri-O-benzoyl-5-iodouridine | | CAS: | 2880-91-3 | | MF: | C30H23IN2O9 | | MW: | 682.42 | | EINECS: | | | Product Categories: | | | Mol File: | 2880-91-3.mol |  |
| | 2',3',5'-Tri-O-benzoyl-5-iodouridine Chemical Properties |
| Melting point | 171-172 °C | | density | 1.68±0.1 g/cm3(Predicted) | | pka | 7.94±0.10(Predicted) |
| | 2',3',5'-Tri-O-benzoyl-5-iodouridine Usage And Synthesis |
| Uses | 2’,3’,5’-Tri-O-benzoyl-5-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | 2',3',5'-Tri-O-benzoyl-5-iodouridine Preparation Products And Raw materials |
|